HistologiX
HistologiX is a UK-based, GLP/GCP compliant contract research organization specializing in tissue-based biomarker analysis, including histology, IHC, immunofluorescence, in situ hybridization, and digital pathology, serving pharmaceutical and biotechnology clients developing novel therapeutics.
- Company typePrivate
- Founded2005
- HeadquartersNottingham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What HistologiX does
HistologiX is a privately held Contract Research Organization (CRO) founded in 2005 and headquartered at Biocity Nottingham in the United Kingdom. The company specializes in GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) compliant tissue-based biomarker analysis services for pharmaceutical and biotechnology clients developing novel therapeutics, including cell therapies, therapeutic antibodies, oncolytic viruses, immune oncology antibodies, and RNA modifying enzymes. Its service portfolio comprises six core service lines (Histology, Cellular Pathology, Digital Pathology, Immuno-oncology, Tissue Cross-Reactivity, and Clinical Trials) supported by three expertise areas (Cell and Tissue Analysis, Biomarker Investigation, and Therapeutic Antibody Characterisation), using techniques including immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and digital image analysis on automated platforms.
The company's underlying technology stack centers on automated chromogenic and immunofluorescent assay platforms with an emphasis on standardization and repeatability, complemented by digital pathology capabilities for quantitative tissue data generation. HistologiX differentiates through bespoke project design with tailored project teams (Study Directors, Scientists, Client Account Management) and operates as an extension of client in-house laboratories, with all personnel holding Life Science degrees, Master's, or PhD qualifications. The company is a subsidiary within The Niche CRO Group, and in November 2025 it was awarded ISO 9001:2015 certification by the British Standards Institution for its Quality Management System.
HistologiX generates revenue through professional services contracts, with bespoke project-based pricing and multi-year contract cadence typical of specialized CRO engagements. The company operates a sales-led B2B go-to-market, reaching clients through direct outreach via its Client Solutions Team, active presence at industry conferences (BioTrinity, Bionow Oncology, Biomarkers and Precision Medicine), and a social media presence on LinkedIn, Facebook, Twitter, and Instagram. Pricing is quote-based and not publicly disclosed, consistent with a high-touch, relationship-driven niche CRO model rather than a transactional or platform-based offering. The company co-founder Andrew Lawrence passed away in summer 2023.
HistologiX firmographics
Firmographics- Name
- HistologiX
- Legal name
- HistologiX Ltd.
- Website
- https://histologix.co.uk
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HistologiX is a UK-based, GLP/GCP compliant contract research organization specializing in tissue-based biomarker analysis, including histology, IHC, immunofluorescence, in situ hybridization, and digital pathology, serving pharmaceutical and biotechnology clients developing novel therapeutics.
- Ownership category
- akta.pro rank
HistologiX industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Medical Laboratories (621511), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC)
Keywords
Where HistologiX is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
HistologiX business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Bespoke tissue-based biomarker analysis services provided to pharmaceutical and biotech companies under GLP/GCP compliance. Services include histology, immunohistochemistry, immunofluorescence, in situ hybridization, and digital image analysis. Revenue is generated through project-based contracts with tailored project teams including Study Directors, Scientists, and Client Account Management.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Bespoke project-based pricing tailored to individual client requirements and study specifications. |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
HistologiX product offering
Product offeringCore offering
HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) providing specialist tissue-based biomarker analysis services to pharmaceutical and biotechnology companies. Core offerings include histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis across the drug development continuum from discovery through clinical phases, with emphasis on bespoke, tailored project engagements.
Product overview
HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) offering a unified portfolio of tissue-based biomarker analysis services. The company provides six core service lines (Histology, Cellular Pathology, Digital Pathology, Immuno-oncology, Tissue Cross-Reactivity, and Clinical Trials), supported by three expertise areas (Cell and Tissue Analysis, Biomarker Investigation, and Therapeutic Antibody Characterisation). Services span from sample collection and logistics through to data analysis, incorporating techniques including IHC (immunohistochemistry), IF (immunofluorescence), ISH (in situ hybridisation), and digital image analysis. The company also offers specialized toxicology study support and works with cutting-edge therapeutics including cell therapies, oncolytic viruses, and RNA modifying enzymes.
Differentiator
Problem solved
Functional benefit
Products and services
- Histology Specialised staining methods and histological tissue preparation services supporting toxicology studies and pre-clinical research for pharmaceutical and biotech clients.
- Supporting Toxicology Studies Toxicology study support services including picrosirius red staining for collagen fiber assessment to evaluate tissue damage and response in pre-clinical safety studies.
- Cellular Pathology Cellular pathology services providing analysis and characterisation of cellular samples for drug development research.
- Digital Pathology Digital pathology and image analysis services delivering quantitative data generation from tissue samples using immunohistochemistry and digital pathology techniques.
- Immuno-oncology Immuno-oncology testing services supporting the development of immune oncology therapeutic antibodies and related therapeutics through tissue-based analysis.
- Tissue Cross-Reactivity Tissue cross-reactivity studies for safety assessment of therapeutic antibodies, supporting regulatory submissions and pre-clinical development.
- Clinical Trials GCP compliant clinical trial support services for tissue-based biomarker analysis across clinical phase studies.
Companies that use HistologiX
Customer profileSegments2 records
Ideal customer profiles2 records
HistologiX technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
HistologiX partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- The Niche CRO GroupcoreHistologiX is part of The Niche CRO Group, an umbrella organization providing strategic alignment and shared resources across specialized CRO services in the life sciences sector. This affiliation provides organizational scale and credibility within the contract research industry.
Scale indicators2 records
Recent moves3 records
Expansion highlights3 records
HistologiX competitors and assessment
Company assessmentDirect peers
- CellCarta (formerly HistoGeneX): CellCarta is a specialized CRO focused on histopathology, immunohistochemistry, digital pathology, and tissue-based biomarker analysis for pharma and biotech, very similar in scope to HistologiX. Both serve pre-clinical and clinical trial work with GLP/GCP-aligned capabilities.
- Histo-Scientific Research Laboratories (HSRL): HSRL is a GLP-compliant histology and pathology CRO providing IHC, ISH, and tissue-based services to pharma and biotech, directly comparable to HistologiX's pre-clinical histology and toxicology support offerings.
- Flagship Biosciences: Flagship Biosciences is a digital pathology CRO specializing in tissue-based biomarker quantification and IHC image analysis for pharmaceutical clients, directly overlapping HistologiX's digital pathology and immuno-oncology services.
- QualTek Molecular Laboratories: QualTek is a specialty IHC and molecular pathology CRO providing tissue-based biomarker analysis for immuno-oncology and drug development, closely mirroring HistologiX's niche focus on therapeutic antibody characterization and IHC.
- Propath UK: Propath is a UK-based specialist histology and IHC service provider serving pharma and biotech, offering comparable GLP-compliant tissue-based biomarker and digital pathology services to HistologiX in a similar UK/European market.
- Mosaic Laboratories: Mosaic Laboratories is an anatomic and clinical pathology CRO offering IHC, ISH, and tissue-based biomarker services to pharma/biotech sponsors, making it a direct competitor to HistologiX in the GLP-compliant histology niche.
Broad incumbents
- ICON plc: ICON is one of the world's largest CROs offering clinical research, bioanalytical, and central lab services, including histology and biomarker capabilities, competing with HistologiX for global clinical trial support work.
- Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a global CRO with central laboratory and anatomic pathology services that overlaps HistologiX's clinical trial tissue analysis, though it competes as a full-service incumbent rather than a specialist.
- Charles River Laboratories: Charles River is a global full-service CRO offering preclinical research, safety assessment, and discovery services that includes histopathology and tissue-based biomarker capabilities as part of a much broader portfolio, competing with HistologiX for outsourced histopathology work.
- NeoGenomics: NeoGenomics operates a specialty oncology-focused clinical laboratory with extensive IHC and molecular pathology capabilities, providing a broader-scale alternative for tissue-based biomarker services that competes with HistologiX in the oncology testing space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
HistologiX social profiles
Digital presenceHistologiX compliance and trust
Trust signalCompliance3 records
HistologiX financial estimates
Financial estimateRevenue estimate
Valuation estimate
HistologiX leadership team
Management profileNumber of profiles
Profiles1 record
HistologiX funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HistologiX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HistologiX
What does HistologiX do?
HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) providing specialist tissue-based biomarker analysis services to pharmaceutical and biotechnology companies. Core offerings include histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis across the drug development continuum from discovery through clinical phases, with emphasis on bespoke, tailored project engagements.
Is HistologiX a public or private company?
HistologiX is a private company. It is classified as corporate owned and is currently operating.
When was HistologiX founded?
HistologiX was founded in 2005. It employs 11 to 50 people.
Where is HistologiX based?
HistologiX is headquartered in Nottingham, United Kingdom, in the Europe region.
How does HistologiX make money?
One revenue line is on record: contract Research Services.
Who are HistologiX's main competitors?
Direct peers on record are CellCarta (formerly HistoGeneX), Histo-Scientific Research Laboratories (HSRL), Flagship Biosciences, QualTek Molecular Laboratories, Propath UK and Mosaic Laboratories. Broad incumbents are ICON plc, Labcorp Drug Development (formerly Covance), Charles River Laboratories and NeoGenomics.
Does HistologiX have an API?
No public API is recorded for HistologiX.
What industry is HistologiX in?
HistologiX's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.